Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loteprednol Etabonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 14/20 | 1.00 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.75 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | USP2 | O75604 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | IL6 | P05231 | 1/20 | 0.57 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.57 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 1/20 | 0.57 |
| ▸ | GLUL | P15104 | 1/20 | 0.57 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.57 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loteprednol Etabonate SCHEMBL23907 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL3822250 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL12738239 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL12045348 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL15325052 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL23765700 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL3413440 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL13379816 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL22078123 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 | |
| Loteprednol Etabonate SCHEMBL506024 | 1.00 | NR3C1 (1.00) | NR3C1PGRABCB11NR1I2ABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INC. | 2012-02-23 | — | — | US | disclosed |
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL BV | 2010-04-08 | — | — | US | disclosed |
| US-20100003334-A1 | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use | BAUSCH & LOMB INCORPORATED (US) | 2010-01-07 | — | — | US | disclosed |
| EP-1677761-B1 | SUSPENSION OF LOTEPREDNOL ETABONATE AND TOBRAMYCIN FOR TOPICAL OPHTHALMIC USE | BAUSCH & LOMB (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2006083840-A1 | COMBINATION OF LOTEPREDNOL ETABONATE AND TOBRAMYCIN FOR TOPICAL OPHTHALMIC USE | BAUSCH & LOMB INCORPORATED (US) | 2006-08-10 | — | — | WO | disclosed |
| EP-1677761-A1 | SUSPENSION OF LOTEPREDNOL ETABONATE AND TOBRAMYCIN FOR TOPICAL OPHTHALMIC USE | BAUSCH & LOMB INCORPORATED (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050197303-A1 | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use | BAUSCH & LOMB INCORPORATED | 2005-09-08 | — | — | US | disclosed |
| WO-2005044231-A1 | SUSPENSION OF LOTEPREDNOL ETABONATE AND TOBRAMYCIN FOR TOPICAL OPHTHALMIC USE | BAUSCH & LOMB INCORPORATED (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050095205-A1 | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use | BAUSCH & LOMB INCORPORATED | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | CYP21A2, CYP27A1, NR3C2 | NR3C1 31/4885PGR 1367/4885ABCB11 130/4885 |
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | CYP21A2, CYP27A1, NR3C2 | NR3C1 31/4885PGR 1367/4885ABCB11 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.